Altimmune's Pemvidutide Shows Concurrent Antifibrotic Effects in MASH via Multiple NITs and qFibrosis

What happened

Altimmune announced new analyses from the IMPACT Phase 2b trial demonstrating that pemvidutide, a balanced GLP-1/glucagon dual agonist, produced concurrent improvements across multiple non-invasive tests (NITs) of MASH activity and fibrosis at 24 weeks. The data also showed fibrosis regression as measured by qFibrosis and confirmed by AI-based digital pathology, reinforcing the drug's antifibrotic potential. These results build on the previously reported 48-week NIT data, which showed highly significant reductions in ELF, liver stiffness, and liver fat, though biopsy-based fibrosis improvement at 24 weeks was not statistically significant in the earlier readout. The current analyses aim to address that gap by using advanced imaging and AI to demonstrate a consistent antifibrotic signal, which could bolster the case for pemvidutide's registrational MASH Phase 3 program. Despite this positive incremental data, the stock remains under pressure from broader market skepticism about Altimmune's funding and competitive positioning in a crowded GLP-1 landscape.

Implication

The new data provide additional mechanistic support for pemvidutide in MASH, potentially strengthening Altimmune's position in partnership discussions and regulatory interactions. However, the market has shown a pattern of 'sell the news' reactions to positive data, as seen after the 48-week IMPACT update, suggesting that investors are demanding more concrete evidence of commercial viability. The main unresolved risk remains the Phase 3 MASH biopsy endpoint, where fibrosis improvement must be statistically significant for accelerated approval. Concurrently, Altimmune's capital needs for both MASH and obesity Phase 3 programs are substantial, and the absence of a major partnership keeps dilution risk elevated. Therefore, while this data is encouraging, it does not change the binary nature of the investment—long-term value creation depends on successful Phase 3 execution and securing non-dilutive funding.

Thesis delta

The new qFibrosis and AI-based pathology data strengthen the antifibrotic narrative for pemvidutide, providing more granular evidence of fibrosis regression that was not clearly captured by standard biopsy at 24 weeks. However, the DeepValue report already factored in strong NIT signals, so this update does not fundamentally alter the investment thesis. The core uncertainty remains whether pemvidutide can deliver statistically significant fibrosis improvement on biopsy in Phase 3, which is the rate-limiting step for regulatory approval and commercial value.